On February 14, TYGES announced that its innovative third-generation CD20 antibody MIL62 had been approved for marketing for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first domestic drug approved for this indication.
NMOSD is a rare autoimmune disease of the central nervous system. It occurs most often in young and middle-aged adults, especially women, and is associated with high relapse and disability rates. In severe cases, it can lead to vision loss and paralysis. NMOSD was included in China’s first list of rare diseases in 2018. The disease usually has an acute or subacute onset and can progress rapidly. About 90% of patients relapse within three years, and patients face a heavy disease and economic burden.
In 2021, TYGES initiated a Phase Ib/III clinical study of this drug to evaluate the safety and efficacy of MIL62 in patients with NMOSD. The study reached its preset endpoint and was unblinded in March 2025. According to the press release, this was the first Phase III clinical trial in NMOSD in China to meet its primary endpoint, providing the first prospective randomized controlled evidence for domestic clinical practice in NMOSD.
At the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis, TYGES presented detailed Phase III trial results in an oral presentation. As of the date the study reached its primary endpoint, the median follow-up times for the MIL62 monotherapy group and the placebo group were 26.29 weeks and 22.14 weeks, respectively, and a total of 23 first relapses were adjudicated by the independent clinical endpoint committee.
For the primary endpoint, the proportion of patients experiencing disease relapse was significantly lower in the MIL62 group than in the placebo group, at 4.4% versus 45.7%, with HR=0.069 and P<0.001. These data showed that MIL62 monotherapy reduced the risk of disease relapse by 93.1%, demonstrating statistically significant therapeutic benefit. Meanwhile, the median time to relapse was not reached in the MIL62 group, whereas it was only 21 weeks in the placebo group, reflecting the strong effect of MIL62 monotherapy in preventing relapse.
For secondary endpoints, MIL62 monotherapy significantly reduced the annualized relapse rate and annualized hospitalization rate for relapse, both 9.2% versus 118% with RR=0.078 and P<0.001, as well as the annualized incidence of cumulative active MRI lesions, 4.8% versus 145.1% with RR=0.033 and P<0.001. These findings indicate that MIL62 has significant advantages in controlling both clinical relapse and radiologic disease activity. In addition, patients receiving MIL62 monotherapy showed clear trends toward stability or improvement in quantified neurologic impairment scores and quality-of-life assessments.
In terms of safety, the overall safety of the MIL62 monotherapy group showed no clear difference from the placebo group and demonstrated good safety and tolerability. No new safety signals were observed with MIL62 monotherapy. Most treatment-related adverse events were Grade 1 or 2, of low severity, and readily manageable. At the same time, there were no treatment-related deaths and no patients discontinued treatment because of treatment-related adverse events.
According to the Insight database, four drugs for NMOSD have previously been approved in China: ravulizumab, eculizumab, inebilizumab, and satralizumab, all of them imported drugs. The approval of MIL62 breaks the import monopoly and makes it the first domestic drug approved for NMOSD.